<DOC>
	<DOCNO>NCT00475800</DOCNO>
	<brief_summary>This 39-week , open label study design ass long-term efficacy , safety tolerability lumiracoxib 100mg od patient osteoarthritis ( OA ) knee participate 13-week core CCOX189A2360 study .</brief_summary>
	<brief_title>Efficacy Safety Lumiracoxib Patients With Primary Knee Osteoarthritis ( OA )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Have complete core CCOX189A2360 study Males females 18 year old Treatment extension study consider appropriate treat physician Noncompliance major protocol violation core study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>celecoxib</keyword>
	<keyword>Cox-2</keyword>
	<keyword>knee</keyword>
</DOC>